Sherritt International Corporation

DB:HRT Stock Report

Market Cap: €46.0m

Sherritt International Valuation

Is HRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HRT (€0.11) is trading below our estimate of fair value (€4.07)

Significantly Below Fair Value: HRT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HRT?

Key metric: As HRT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HRT. This is calculated by dividing HRT's market cap by their current revenue.
What is HRT's PS Ratio?
PS Ratio0.5x
SalesCA$147.90m
Market CapCA$67.54m

Price to Sales Ratio vs Peers

How does HRT's PS Ratio compare to its peers?

The above table shows the PS ratio for HRT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
BNN BRAIN Biotech
1.2x8.5%€69.9m
IBU IBU-tec advanced materials
0.6x19.2%€29.0m
DLX Delignit
0.3x10.2%€22.3m
NTG Nabaltec
0.6x5.1%€122.8m
HRT Sherritt International
0.5x5.7%€67.5m

Price-To-Sales vs Peers: HRT is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.7x).


Price to Sales Ratio vs Industry

How does HRT's PS Ratio compare vs other companies in the European Metals and Mining Industry?

35 CompaniesPrice / SalesEstimated GrowthMarket Cap
HRT 0.5xIndustry Avg. 0.7xNo. of Companies35PS00.81.62.43.24+
35 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HRT is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Metals and Mining industry average (0.7x).


Price to Sales Ratio vs Fair Ratio

What is HRT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HRT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio0.1x

Price-To-Sales vs Fair Ratio: HRT is expensive based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HRT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.11
€0.38
+258.2%
39.1%€0.53€0.23n/a2
Nov ’25€0.12
€0.38
+224.5%
39.1%€0.53€0.23n/a2
Oct ’25€0.14
€0.43
+210.5%
23.1%€0.54€0.33n/a2
Sep ’25€0.12
€0.43
+250.6%
23.1%€0.54€0.33n/a2
Aug ’25€0.13
€0.43
+224.4%
23.1%€0.54€0.33n/a2
Jul ’25€0.17
€0.44
+154.1%
23.1%€0.54€0.34n/a2
Jun ’25€0.20
€0.44
+117.1%
23.1%€0.54€0.34n/a2
May ’25€0.21
€0.44
+109.7%
23.1%€0.55€0.34n/a2
Apr ’25€0.18
€0.44
+142.8%
23.1%€0.54€0.34n/a2
Mar ’25€0.18
€0.40
+126.7%
26.5%€0.55€0.31n/a3
Feb ’25€0.19
€0.51
+169.6%
47.5%€0.85€0.31n/a3
Jan ’25€0.19
€0.55
+185.5%
39.9%€0.85€0.38n/a3
Dec ’24€0.22
€0.55
+152.1%
39.9%€0.85€0.38n/a3
Nov ’24€0.28
€0.63
+127.6%
29.7%€0.87€0.42€0.123
Oct ’24€0.27
€0.63
+129.3%
27.2%€0.86€0.45€0.143
Sep ’24€0.31
€0.63
+104.3%
27.2%€0.86€0.45€0.123
Aug ’24€0.32
€0.63
+94.2%
27.2%€0.86€0.45€0.133
Jul ’24€0.35
€0.72
+106.1%
29.7%€1.01€0.50€0.173
Jun ’24€0.33
€0.72
+116.4%
29.7%€1.01€0.50€0.203
May ’24€0.38
€0.72
+90.2%
29.7%€1.01€0.50€0.213
Apr ’24€0.36
€0.72
+102.6%
30.9%€1.03€0.52€0.183
Mar ’24€0.35
€0.65
+83.0%
38.3%€1.05€0.38€0.184
Feb ’24€0.40
€0.72
+78.9%
27.4%€1.03€0.55€0.194
Jan ’24€0.34
€0.75
+121.8%
38.6%€1.18€0.41€0.194
Dec ’23€0.35
€0.75
+111.1%
38.6%€1.18€0.41€0.224
Nov ’23€0.34
€0.73
+115.6%
39.3%€1.19€0.41€0.284

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies